Humacyte, Inc. (HUMA)
(Real Time Quote from BATS)
$5.82 USD
-0.04 (-0.60%)
Updated Jul 10, 2024 02:22 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
HUMA 5.82 -0.04(-0.60%)
Will HUMA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HUMA
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors
Should You Buy Humacyte (HUMA) Ahead of Earnings?
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q2 Loss, Tops Revenue Estimates
Other News for HUMA
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
Peering Into Humacyte's Recent Short Interest
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
Humacyte presents positive preclinical data for BVP program
3 Best Stocks to Buy Now, 6/18/2024, According to Top Analysts